About: SARS-CoV-2 Spike S1 Receptor Binding Domain undergoes Conformational Change upon Interaction with Low Molecular Weight Heparins

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 Spike S1 Receptor Binding Domain undergoes Conformational Change upon Interaction with Low Molecular Weight Heparins Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-CoV-2 Spike S1 Receptor Binding Domain undergoes Conformational Change upon Interaction with Low Molecular Weight Heparins
Creator	Li, Lima, Marcelo Skidmore, Mark Yates, Edwin Fernig, David Guerrini, Marco Miller, Gavin Mycroft-West, Courtney Turnbull, Jeremy Bisio, Antonella Elli, Stefano Forsyth, Nicholas Guimond, Scott Nunes, Quentin Procter, Patricia Rudd, Timothy
Source	BioRxiv
abstract	The dependence of the host on the interaction of hundreds of extracellular proteins with the cell surface glycosaminoglycan heparan sulphate (HS) for the regulation of homeostasis is exploited by many microbial pathogens as a means of adherence and invasion. The closely related polysaccharide heparin, the widely used anticoagulant drug, which is structurally similar to HS and is a common experimental proxy, can be expected to mimic the properties of HS. Heparin prevents infection by a range of viruses when added exogenously, including S-associated coronavirus strain HSR1 and inhibits cellular invasion by SARS-CoV-2. We have previously demonstrated that unfractionated heparin binds to the Spike (S1) protein receptor binding domain, induces a conformational change and have reported the structural features of heparin on which this interaction depends. Furthermore, we have demonstrated that enoxaparin, a low molecular weight clinical anticoagulant, also binds the S1 RBD protein and induces conformational change. Here we expand upon these studies, to a wide range of low molecular weight heparins and demonstrate that they induce a variety of conformational changes in the SARS-CoV-2 RBD. These findings may have further implications for the rapid development of a first-line therapeutic by repurposing low molecular weight heparins, as well as for next-generation, tailor-made, GAG-based antiviral agents, against SARS-CoV-2 and other members of the Coronaviridae.
has issue date	2020-04-29(xsd:dateTime)
bibo:doi	10.1101/2020.04.29.068486
has license	biorxiv
sha1sum (hex)	8d0d7f941bd7b65a7c38e409efb14b0e4b0320f0
schema:url	https://doi.org/10.1101/2020.04.29.068486
resource representing a document's title	SARS-CoV-2 Spike S1 Receptor Binding Domain undergoes Conformational Change upon Interaction with Low Molecular Weight Heparins
schema:publication	bioRxiv
resource representing a document's body	covid:8d0d7f941bd7b65a7c38e409efb14b0e4b0320f0#body_text
is schema:about of	named entity 'implications' named entity 'enoxaparin' named entity 'coronavirus' named entity 'repurposing' named entity 'extracellular' named entity 'mimic' named entity 'Running' named entity 'Binding' named entity 'LMW' named entity 'ADHERENCE' named entity 'ANTICOAGULANT' named entity 'LOW MOLECULAR WEIGHT HEPARINS' named entity 'ANTIVIRAL AGENTS' named entity 'PREVENTS' named entity 'UNFRACTIONATED HEPARIN' named entity 'VIRUSES' named entity 'THERAPEUTIC' named entity 'CELL SURFACE' named entity 'MEMBERS' named entity 'CONFORMATIONAL CHANGE' named entity 'A COMMON' named entity 'SIMILAR' named entity 'MEANS' named entity 'PREVIOUSLY' named entity 'SARS-COV-2' named entity 'FINDINGS' named entity 'EXPERIMENTAL' named entity 'THESE' named entity 'GAG' named entity 'ASSOCIATED' named entity 'HAVE' named entity 'induces' named entity 'invasion' named entity 'exogenously' named entity 'protein' named entity 'binds' named entity 'interaction' named entity 'therapeutic' named entity 'common' named entity 'molecular weight' named entity 'members' named entity 'polysaccharide' named entity 'microbial' named entity 'first-line' named entity 'conformational change' named entity 'pathogens' named entity 'Heparin' named entity 'heparin' named entity 'SARS-CoV-2' named entity 'exogenously' named entity 'SARS-CoV-2' named entity 'anticoagulant' named entity 'unfractionated heparin' named entity 'RBD' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'range' named entity 'mucosal' named entity 'anticoagulant' named entity 'PBS' named entity 'Surface Plasmon Resonance' named entity 'phosphate-buffered saline' named entity 'SARS-CoV-2' named entity 'anticoagulant' named entity 'fluidics' named entity 'Merck Millipore' named entity 'FGF2' named entity 'carbohydrate' named entity 'prophylaxis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software